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ABSTRACT
Hepatitis B virus (HBV) infection is a major cause of liver disease worldwide. Eight genotypes and 24
subgenotypes of HBV have been identified. The aim of this study was to determine the distribution of
HBV genotypes, subgenotypes and subtypes, and to understand HBV genetic variability in the HBV
genome circulating in Iranian provinces. Two hundred and forty-nine sera from HBV-infected patients
living in 25 provinces of Iran were collected (2004–2007). A part of the HBV S ⁄ pol and whole BCP ⁄C genes
were amplified, sequenced and then subjected to phylogenetic, recombination and genetic variability
analysis. Results revealed genotype D of HBV in all samples and subgenotypes D1 (98.52%), D2 (0.74%)
and D3 (0.74%) among Iranian patients living in different provinces of Iran. Subtypes ayw2 (94.4%), ayw1
(2.8%), ayw3 (2%) and ayw4 (0.4%) were deduced, on the basis of HBV small surface antigen (HBsAg)
amino acid sequences. The mean percentage intra-genotypic distance of S plus core regions was 2.8%;
the mean percentage inter-genotypic distance of this region between Iranian strains and genotype D
isolates was 3.1%; and this rate for other genotypes was 5.2–11.4%. Various rates of point mutations have
been found within different HBV genes, e.g. HBsAg (17.2%), precore-G1896A (59.5%) and Basal core
promoter (BCP) double mutations (49.2%), whereas no recombination was found. In conclusion, these
results indicate that the only genotype circulating in the provinces of Iran is genotype D. There exist high
genetic variabilities in the S ⁄ pol and BCP ⁄C regions among the Iranian HBV isolates.
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INTRODUCTION
Hepatitis B virus (HBV) infection is a global
health problem, with more than 350 million people
being chronically infected worldwide. HBV is
the major aetiological agent of acute and chronic
liver disease, including fulminant hepatitis,
cirrhosis and hepatocellular carcinoma (HCC) [1].
Traditionally, HBV has been classified into nine
serological types [2]. Currently, on the basis of a
nucleotide diversity of >8% in the entire genome,
eight genotypes of HBV (A–H) have been identified
[3–5]. HBV isolates have also been further classified
into 24 subgenotypes on the basis of a >4% (but
<8%) difference in the complete nucleotide
sequences [6]. These genotypes show distinct vari-
ation in their geographical distribution in theworld.
Genotyping and serotyping assays are useful
tools in understanding the epidemiology of HBV
infection. Indeed, there is increasing evidence
showinga correlationbetween the clinical outcomes
of HBV infection and genetic diversity [7,8]. With
knowledge of the HBV genomic diversities, clinical
practice and outcomes will definitely improve.
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Iran is a Middle Eastern country located in
south-west Asia. A recent report showed that
over 35% of Iran’s population has been exposed
to HBV and approximately 2% are chronically
infected [9]. The genotypes and genome
sequences of HBV prevalent in Iran have not
been sufficiently evaluated in all provinces, and
only limited information is available from Tehran,
the capital of Iran [10,11]. In the present study,
HBV genotype distribution and its genetic vari-
ability were determined among Iranian HBV-
infected individuals from the provinces of Iran.
MATERIALS AND METHODS
Patients
The aim of the study was to determine HBV genotype ⁄ subge-
notype ⁄ subtype distribution and also to understand HBV
genetic variability in the whole of Iran. Samples were collected
from throughout the country. Iran consists of 30 provinces,
which can be divided into five different geographical regions
(Fig. 1). In this regard, a cooperative network was set up to
connect provincial health centres, which were asked to collect
HBV-positive sera from patients living in their own province
between January 2004 and July 2007. Samples were regularly
sent to the Research Centre for Gastroenterology and Liver
Diseases in Tehran. Unfortunately, samples from five provinces
could not be obtained, despite frequent requests. In the end, 280
blood samples were collected from patients with HBV infection
that covered the major regions of Iran (25 ⁄ 30 provinces, 85% of
the country). The numbers, percentages and geographical
distribution of these patients are shown in Fig. 1. Informed
consent was obtained from all the patients, and the study
protocol was reviewed and approved by the Ethics Committee
at the Research Centre for Gastroenterology and Liver Diseases,
Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Serological and biochemical markers
Serological markers of HBV infection, which included HBsAg,
anti-HBV core (anti-HBc), HBV pre-core Antigen (HBeAg), and
anti-HBe, were determined with commercially available ELISA
kits (DIA PRO Diagnostic Bioprobes, Srl., Italy). The sera were
also tested using liver function tests such as alanine amino-
transferase, aspartate aminotransferase, direct bilirubin total
bilirubin and alkaline phosphatase.
Amplification and sequencing
HBV DNA was extracted with an QIAamp UltraSens Virus kit
(Qiagen, Hilden, Germany). A 402-bp fragment covering a
region of the S ⁄Pol genes was amplified (with marked hetero-
geneity among genotypes), flanked by a conserved region to
allow equal amplification of all genotypes. HBV BCP ⁄ preC ⁄C
gene sequences were chosen for amplification (784 bp), in order
to determine the basal core promoter and anyprecoremutations
[12]. The partial HBV S genes of 249 and 136 HBV BCP ⁄ preC ⁄C
gene sequences were amplified successfully. Amplicons were
cleaned up using a QIA Quick Gel Extraction kit (Qiagen). The
BigDye Terminator v3.1 cycle sequencing kit (Applied Biosys-
tems, Foster City, CA, USA) was employed for sequencing. The
ABI PRISM 3130XL Genetic Analyzer (Applied Biosystems)
was utilized for electrophoresis and data collection. All
sequences were analyzed bi-directionally.
Phylogenetic analysis
The combined S plus BCP ⁄ preC ⁄C sequences (1186 bp) of 136
isolates were compared to their corresponding regions of 71
reference sequences retrieved from the GenBank database and
representing all major HBV genotypes and, in particular,
different subgenotypes of genotype D (D1–D5). The sequences
were aligned using CLUSTALX software [13]. The genetic
distances were estimated by a Kimura two-parameter algo-
rithm, and a phylogenetic tree was constructed by the
neighbour-joining method [14]. The reliability of the phyloge-
netic tree was confirmed by a bootstrap resampling test [15].
The analyses and calculated nucleotide differences within and
between the isolate sequences were carried out with the
MEGA program, version 3.1 [16]. Recombination was assessed
using SIMPLOT software [17]. Woolly monkey HBV (GenBank
accession number AF046996) was utilized as an outgroup.
Statistical analysis
Statistical differences were evaluated by chi-square test and
Student’s t-test. Differences were considered significant when
a p value was £0.05.
RESULTS
Demographic and clinical data
In this study, 280 sera were collected from HBV-
infected individuals from different ethnic groups
Caspian Sea
51 (20%)
North Part
Center Part
West Part
36 (14%)
119 (49%)
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Persian
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East Part
Fig. 1. Division of Iranian provinces into five parts on the
basis of geographical location. Numbers and percentages
of patients in each part are shown.
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in 25 provinces of Iran. After successful PCR
amplification (the partial S gene of 249 patients
and the BCP ⁄ preC ⁄C gene of 136 patients), a study
population totalling 249 patients with a mean age
of 40.1 ± 14.5 years (range: 11–80 years), includ-
ing 69.8% males and 30.2% females, was
enrolled. The clinical profile of these patients
is presented in Table 1.
Phylogenetic analysis and genetic distance
The 1085-bp fragment used for phylogenetic tree
analysis was generated from two different blocks
of the HBV BCP ⁄ preC ⁄C gene with 731-bp
sequences plus a partial HBV S gene with
355-bp gene sequences taken from 136 HBV
Iranian isolates. The phylogenetic tree analysis
revealed that all Iranian isolates were classified as
genotype D and the majority belonged to subge-
notype D1 (97%). One isolate was grouped as
subgenotype D2 and another belonged to subge-
notype D3 (Fig. 2). Genetic distance was esti-
mated, based on a 1085-bp region within and
between the HBV isolates. The mean percentage
of nucleotide distance (intra-genotype) for Iranian
isolates was 2.8%, whereas the nucleotide dis-
tance (inter-genotype) with other D genotypes
was 3.1% (Table 2). The mean percentage of intra-
genotype nucleotide distance between D1 Iranian
isolates and other D1 subgenotypes from the
GenBank database was 2.4%.
On the basis of the phylogenetic tree results, the
Iranian isolates were, interestingly, grouped into
two distinct branches within subgenotype D1
(Fig. 2, shown by arrows). Comparison of these
two groups revealed a correlation in three resi-
dues within open reading frame C, exactly in the
nucleotide positions 2080, 2107 and 2167, respec-
tively. Nucleotide T at position 2080 co-appeared
with C2107 and T2167 (called D1a), whereas,
when A ⁄C ⁄G was located at position 2080, the
coincidence of T2107 and C2167 was observed
(called D1b) (Fig. 3). These patterns were found
among 123 isolates (90.4%). The mean percentage
of nucleotide distance between these two groups
was 2.9%, close to the overall inter-genotype
distance of all Iranian isolates. Interestingly, these
two groups were also linked with another nucle-
otide position in ORF S of 104 from 123 isolates
(84.5%). The nucleotide C499 (in the HBsAg) was
detected in 94.7% of group D1a isolates, whereas
this rate for group D1b was only 31.2%.
Interestingly, the BCP double mutation
(A1762T ⁄G1764A) was more common within
group D1a, and the other BCP double mutation
(G1764T ⁄T1766G) was clearly more common in
group D1b (Table 2). Analyses of demographic
and clinical properties of patients among groups
D1a and D1b did not show a significant differ-
ence. Moreover, no specific geographical associa-
tion was found between these two groups.
HBV subtyping
The HBsAg gene from 249 Iranian HBV isolates
was amplified, which covered the major immu-
nogenic region ‘a’ determinant domain. Subtypes
were deduced from the sequence of the viral
genome region encoding the HBsAg [18]. The
majority of Iranian isolates were ayw2 (94.4%),
based on Arg122, Lys160 and Pro127; seven
isolates were ayw1 (2.8%), based on Arg122,
Lys160 and Pro127 plus Phe134 and ⁄ or Ala159;
five isolates were ayw3 (2%), based on Arg122,
Lys160 and Thr127; finally, one isolate was ayw4
(0.4%), based on Arg122, Lys160 and Leu127.
Interestingly, the subtype of one isolate was
unknown because of atypical substitution at
subtype-specifying residues (Ser127 because of a
CCT ﬁ TCT mutation).
Table 1. Demographic, clinical, serological and biochemical information on the 249 patients infected by hepatitis B virus
Clinical status
Number
(%)
Sex
Age (years) HBsAg+ Anti-HBc+ HBeAg+ Anti-HBe+
ALT
(IU/L)
AST
(IU/L)
T-Bil
(mg/dL)
D-Bil
(mg/dL)
ALP
(U/L)M F
Asymptomatic
carriers
31 (12.4) 18 13 36.7 ± 11.8 30 31 0 31 26.2 ± 9.6 24.1 ± 6.4 0.81 ± 0.35 0.18 ± 0.12 148.7 ± 46.9
Chronic hepatitis 196 (78.8) 136 60 39.1 ± 13.6 194 196 43 153 54.8 ± 41.6 47.9 ± 22.6 1.4 ± 0.9 0.6 ± 0.5 204 ± 68.5
Acute hepatitis 5 (2) 5 0 42.6 ± 14.1 5 5 4 1 328.6 ± 177.2 244.4 ± 71.4 10.1 ± 12.4 4.1 ± 3.1 338.2 ± 31.5
Liver cirrhosis 14 (5.6) 12 2 54.4 ± 12.5 13 14 3a 10a 86.6 ± 109.4 107.9 ± 69.8 7.4 ± 7.3 2.5 ± 3.5 436.5 ± 272.8
HCC 3 (1.2) 3 0 70.6 ± 9.01 3 3 0 3 71 ± 24.6 174.3 ± 142.2 5.4 ± 7 1.6 ± 2.2 458.3 ± 274.5
Total 249 (100) 174
(69.8%)
75
(30.2%)
40.1 ± 14.5 245 249 50 198 57.7 ± 75.4 53.7 ± 49.1 1.8 ± 3.1 0.7 ± 1.2 216.4 ± 130.1
ALT, alanine aminotransferase; AST, aspartate aminotransferase; D-Bil, direct bilirubin; T-Bil, total bilirubin; ALP, alkaline phosphatase; HCC, hepatocellular carcinoma.
aOne patient’s test results were negative for both HBeAg and anti-HBe antibody.
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Fig. 2. A phylogenetic tree constructed using the neighbour-joining method, based on two different blocks of the HBV.
BCP ⁄preC ⁄C with 731-bp sequences plus partial HBV HBsAg with 355-bp gene sequences taken from 136 HBV Iranian
isolates were compared with the corresponding region of 71 reference sequences retrieved from the GenBank database
representing all major HBV genotypes and subgenotypes of genotype D.
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Genetic variability in the S ⁄pol and BCP ⁄C
genes
Various point mutations in the sequence of HBsAg
have been found among Iranian HBV isolates
(Fig. 4). The most frequent mutations in Iranian
isolates were Ser143Leu (5.2%), Ile10Leu (4.4%),
Gln101Arg (1.6%), Pro120Ser (1.6%), Thr118Ala
(0.8%), Ser136Tyr (0.8%) and Thr118Lys (0.8%).
Interestingly, one isolate had an insertion (15
nucleotides) between nucleotides 222 and 223
which resulted in an LLPGS amino acid insertion.
The TGG ﬁ TGA stop mutation was detected in
two isolates, and led to a premature stop codon at
position Trp172 in the S gene.
In the studied population, 54 patients (21.6%)
had received lamivudine (100 mg ⁄day) for more
than 1 year. Thirty-one treated patients (57%) had
HBV isolates with drug resistance mutations in the
HBV pol region. Twenty-eight of 31 isolates
(90.32%) had lamivudine resistance mutations,
and three patients had isolates with both lamivu-
dine resistance and adefovir dipivoxile resistance
Table 2. Demographic, serological, biochemical and muta-
tion information on the D1a and D1b patient groups
Group properties
(number of patients)
D1a
75 of 136
(55.1%)
D1b
48 of 136
(35.2%) p-value
A1762T ⁄G1764A double mutation in BCP 16 (21.3%) 3 (6.2%) 0.02
G1764T ⁄T1766G double mutation in BCP 13 (17.3%) 21 (43.7%) 0.01
C nucleotide in position 499 of HBsAg 71 (94.7%) 15 (31.2%) <0.001
T ⁄G ⁄A nucleotide in position 499 of HBsAg 4 (5.3%) 33 (68.8%) <0.001
D1a
D1b
Fig. 3. The nucleotide sequence alignment of the C gene (nucleotides 2078–2174) deduced from the nine GenBank
subgenotype D1 strains and the 39 Iranian isolates from this study. Three positions (2080, 2107 and 2167) are linked
together in 91.2% of Iranian isolates. If T is located at position 2080, there will be C2107 and T2167 (group D1a). If A ⁄C ⁄G
is at position 2080, there will be T at position 2107 and C at position 2167 (group D1b).
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mutations (9.67%). Analysis of the RT region of the
pol gene revealed M204I in 19 patients (61.29%),
L180M + M204I in six patients (19.35%),
L180M + M204V in two patients (6.45%) and
V173L + L180M + M204V in one patient (3.22%).
The L180M + M204V + A181V mutations and
V173L + L180M + M204I + A181T mutations
(lamivudine and adefovir resistance) were
observed in one and two patients, respectively.
The BCP ⁄ preC ⁄C gene from the Iranian HBV
isolates was amplified to identify a double muta-
tion at the BCP region and other mutations at the
preC ⁄C region. The double mutation
A1762T ⁄G1764A was detected in 22 isolates
(16.1%), the mutation G1764A in four (2.9%),
the double mutation G1764T ⁄T1766G in 40
(29.4%), and the mutation T1766G in two
(1.4%). There were 81 isolates (59.5%) with the
G1896A stop precore mutation. The G1899A
mutation was also found in 29 isolates (21.3%).
Most of the Iranian isolates had Thr1858, Gly1862
and Gly1888 in the pregenomic encapsidation
signal sequences; these are common in HBV
genotype D. Interestingly, there were the follow-
ing mutations: T1858C in one isolate, G1862A in
two isolates, and G1862T in five isolates. The
direct repeat 1 sequence at position 1824–1834
was conserved in all the Iranian isolates.
An eight-nucleotide deletion (position 1762–
1770) in two isolates, a nine-nucleotide deletion
(position 1741–1749) in one isolate and a single
base pair deletion in position 1846 in one isolate
have been found and confirmed by resequencing.
Comparison of liver function test (LFT) results
and HBeAg status between BCP ⁄ and precore
mutants and wild-type isolates in chronic patients
was done. There were no significant differences in
mean values of LFT results between these groups.
Among the HBeAg-positive patients, 25.8%
showed wild-type isolates, whereas 15.3% of
patients with BCP mutant isolates were still
detected as being HBeAg-positive as well. All
patients with precore mutants and BCP ⁄precore
mutants were HBeAg-negative. When mean age
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3879 . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2951 . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5772 . . . . . . . . . . . L . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8152 . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7474 . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2679 . . R . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
L018 . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5784 . . R . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
L032 . . R . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3170 . . . . . . . . . . . . . . . P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2305 . . . . . . . . . . . . . . . . . . . A . . . . . . . . T V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . . . . . . . . . . . . . . . . . . . .
1914 . . . . . . . . . . . . . . . . . . . A . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C . . . . . . . .
2024 . . . . . . . . . . . . . . . . . . . K . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3253 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7183 . . . . . . . . . . . . . . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
L004 . . . . . . . . . . . . . . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
L003 . . . . . . . . . . . . . . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
L006 . . . . . . . . . . . . . . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.05 . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
L005 . . . . . . . . . . . . . . . . . . . . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5640 . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . N . . . F . . . . . . . . . E . . . . . . . . . . . . . . . . . . . . . . . . . . . . F . . . . . . . . . . . . . . . . . .
7063 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4661 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . L . . R . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . . .
0.01 . . . . . . . . R . P . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . . . . Q . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8108 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8110 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7149 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8130 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6813 . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7145 . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3173 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3879 . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6436 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3887 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4954 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4760 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
N003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3176 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3271 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6445 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5630 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I . .
3275 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
    a-determinant domain 
Fig. 4. Alignment of amino acids 99–191 of the partial S amino acid sequence of 43 Iranian isolates. The first (3251) is a
wild-type isolate and is depicted in detail.
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and LFT results were compared between the
HBeAg-positive ⁄ anti-HBe-negative group and the
HBeAg-negative ⁄ anti-HBe-positive group, there
were no significant differences in the mean values
of LFT results, but the mean age was significantly
less (p <0.001) in the HBeAg-positive ⁄ anti-HBe-
negative patients than in the HBeAg-nega-
tive ⁄ anti-HBe-positive patients.
DISCUSSION
HBV genotyping has been extensively used
throughout the world; but the results are incom-
plete in some parts and, in particular, the Middle
East region. There is little information on HBV
genotypes in Iran, and this is the first study to
cover the majority of Iranian provinces. On the
basis of a phylogenetic analysis of the S and C
regions of 136 Iranian patients, genotype D was
found to be the predominant genotype of HBV
and was circulating in all provinces of the
country. The majority of Iranian strains were
subgenotype D1, subtype ayw2, whereas small
numbers of D2 ⁄ ayw3 and D3 ⁄ ayw2 isolates were
detected as well. Previous molecular epidemio-
logical studies among Iranian chronic HBV
patients, based on the S and C regions from
chronic patients [11] and on the five complete
genome sequences [12], also demonstrated that
genotype D was the only HBV genotype in the
Iranian population. Additionally, these data were
in accordance with a previous study based on 109
HBV-infected patients, all living in Tehran [19].
HBV genotype D is found worldwide, although it
is relatively rare in northern Europe and in the
Americas [6]. There are reports of the presence of
genotype D in Iran’s neighbouring countries,
including Turkey [20], Afghanistan [12], Pakistan
[21] and Saudi Arabia [22].
Studies on subgenotypes in the Middle East
region are limited to Turkey and Afghanistan;
subgenotypes D1 and D2 were found in Turkey
[20] and subgenotype D1 in Afghanistan [12].
Subgenotypes D1, D2 and D3 have been de-
scribed as widespread throughout the world,
subgenotype D3 was found in Asia (East India),
South Africa, and Europe, subgenotype D4 was
found in Australia [6], and recently, a new
subgenotype, D5, was found in eastern India
and Japan [23]. Although subgenotype D1 was
predominant in this study, subgenotypes D2 and
D3 were also found.
Genetic variability analyses of Iranian isolates
have shown a number of mutations, insertions
and deletions within the sequences of the S and
the C regions. Amino acid substitutions within the
‘a’ determinant domain can lead to conforma-
tional changes. Some of these changes may lead to
important medical and public health issues, such
as vaccine escape, failure of hepatitis B immune
globulin to protect liver transplant patients,
babies being born to carrier mothers, and failures
in detection of HBV carriers with some diagnostic
tests [24,25]. In this study, HBV isolates with
P120T, P120S, T123N and T126S mutations in the
HBV HBs gene were identified, which may cause
problems in diagnostic assays or treatment fail-
ures in hepatitis B immune globulin therapy,
according to previous surveys [24–30]. The most
important mutation in the ‘a’ determinant of
HBsAg is G145R [24]. This mutation is stable
over time and can be transmitted horizontally,
despite the presence of high levels of anti-HBs
[24,25]. Only one isolate with the G145R substi-
tution was detected in this survey. Another
mutation outside the ‘a’ determinant is F183C,
which was found in one isolate. Recently, Oon
et al. [28] have shown that F183C mutation may
reduce affinity for monoclonal antibody. The
present results showed that the frequency of
HBsAg mutants in Iranian HBV-infected patients
is 17.2% (43 ⁄ 249 isolates). As a viral HBV popu-
lation infecting a host is usually distributed as a
quasi-species, variants are expected to coexist
with wild-type strains in most carriers. Direct
sequencing of the PCR products cannot reveal a
variant present in the sample as a minor popu-
lation, and the true proportion of patients carry-
ing HBsAg variants may be higher [31]. Recent
studies indicated that the prevalence of HBsAg
escape mutants among random chronic carriers
could be as high as 6–12% [32].
As lamivudine is the only antiviral agent
prescribed for HBV infection treatment in Iran,
lamivudine resistance mutations may be observed
among Iranian patients. Analysis of the HBV RT
region of the HBV pol gene revealed various point
mutations for lamivudine drug resistance in
Iranian patients who received lamivudine.
Thirty-one patients (57%) from among 54 treated
individuals showed a variety of lamivudine drug
resistance mutations. This rate is relatively high
compared with the 15–20% drug resistance per
year after lamivudine antiviral therapy [7].
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Other important mutations in the HBV genome
can occur in the HBV C region. There were two
major groups of mutations, including precore
mutation and BCP double mutations, that may
affect HBeAg expression. In the present survey,
G1896A was found in 59.5% of the patients
(81 ⁄ 136). G1896A can create a stop codon in the
precore region that prevents production of
HBeAg. Other important mutations are BCP
mutations that can occur at positions 1762 and
1764 (A1762T ⁄G1764A). These double mutations
also decrease HBeAg production [33]. In this
study, the A1762T ⁄G1764A double mutations
were detected in 15.4% (21 ⁄ 136); moreover, the
G1764T ⁄T1766G double mutations were identi-
fied in 29.4% (40 ⁄ 136). There were no significant
difference in mean values of LFT results between
chronic patients with BCP ⁄precore mutant iso-
lates and chronic patients with wild-type isolates.
Recent studies indicated that the A1762T ⁄G1764A
mutation correlates with development of HCC
[34,35], which was in agreement with the patients
who had HCC in this study. The G1764T ⁄T1766G
double mutation has been proposed to form a
putative new binding site for the transcription
factor hepatocyte nuclear factor 3, and is thought
to be a rare mutation [36]. In contrast, this rare
mutation was found in 31% of patients in an
independent study [37], which was close to the
present findings (29.4%).
In conclusion, HBV genotype D and subgeno-
type D1 ⁄ ayw2 were predominant in Iranian
patients, and subgenotypes D2 ⁄ ayw3 and
D3 ⁄ ayw2 were also found in the country. These
results indicate that there is high genetic variability
in the HBV HBs, pol and core regions among
Iranian HBV isolates.
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